NewAmsterdam Pharma’s VINCENT Study: A Promising Step in Cardiovascular Treatment

Newamsterdam Pharma Company N.V. ((NAMS)) announced an update on their ongoing clinical study.

Study Overview: NewAmsterdam Pharma is conducting a Phase 2 clinical trial titled A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study. The study aims to assess the impact of obicetrapib, both alone and in combination with evolocumab, on lowering Lp(a) levels in patients with mild dyslipidemia, a condition linked to cardiovascular risk.

Intervention/Treatment: The trial tests two interventions: obicetrapib, a drug administered at 10 mg daily, and a combination of obicetrapib with evolocumab (Repatha®), administered as 140 mg every other week. These treatments aim to reduce elevated Lp(a) levels, which are associated with cardiovascular diseases.

Study Design: This open-label, sequential study involves an initial 8-week treatment with obicetrapib, followed by an 8-week combination therapy with obicetrapib and evolocumab. The primary purpose is treatment, with no masking involved, allowing researchers to directly observe the effects of the interventions.

Study Timeline: The study began on July 3, 2024, with primary completion expected by 2025. The latest update was submitted on July 31, 2025, indicating ongoing recruitment and progress.

Market Implications: This study update could positively influence NewAmsterdam Pharma’s stock performance by showcasing potential advancements in cardiovascular treatment. Investors may view this as a strategic move to capture market share in the dyslipidemia treatment sector, potentially impacting competitors focusing on similar therapies.

The study is ongoing, with further details available on the ClinicalTrials portal.